Loading
Hypertension / Diabetes · Journal article
Osteoarthritis and Cartilage Open · August 11, 2026
Well-designed and adequately powered for the question it asks.
In a large Swedish population-based cohort of 48,778 opioid-naïve individuals with incident osteoarthritis, hypertension and diabetes—alone or together—were associated with increased risk of both opioid initiation and progression to long-term use. The risk of long-term opioid use was substantially higher (RR 1.63–1.69) than for initial opioid dispensation (RR 1.15–1.16), with cumulative risk peaking in the first year after OA diagnosis.
Population-based open cohort study using linked Swedish health registers. Opioid-naïve residents of Skåne region aged 35–75 with incident OA diagnosis 2008–2019, resident ≥10 consecutive years, no prior OA or cancer diagnosis, no opioid dispensation in 2 years before OA diagnosis.. Intervention: Presence of diabetes and/or hypertension at or after OA diagnosis.. Compared with: Metabolically healthy individuals (no diabetes and no hypertension).. n = 48,778. Skåne region, Sweden; approximately 1.4 million population base..
Hypertension alone associated with higher risk of first opioid dispensation: RR 1.16 [95% CI 1.12; 1.20] Both hypertension and diabetes associated with higher risk of first opioid dispensation: RR 1.15 [1.10; 1.21] Diabetes alone associated with long-term opioid use: RR 1.63 [1.21; 2.20]
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians managing osteoarthritis should recognize that patients with comorbid hypertension and especially diabetes face substantially elevated risk of both initiating opioid therapy and progressing to long-term use. This finding reinforces guideline recommendations against opioids in OA and highlights the need for targeted safer pain management strategies, particularly in the first year after OA diagnosis when risk is highest, for patients with metabolic comorbidities.
A large population-based register cohort study with rigorous design, clear relative risk estimates with confidence intervals for both primary outcomes, and adequate statistical adjustment, though observational design limits causal inference.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing osteoarthritis should recognize that patients with comorbid hypertension and especially diabetes face substantially elevated risk of both initiating opioid therapy and progressing to long-term use. This finding reinforces guideline recommendations against opioids in OA and highlights the need for targeted safer pain management strategies, particularly in the first year after OA diagnosis when risk is highest, for patients with metabolic comorbidities.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective. To estimate the associations of diabetes and/or hypertension with (i) initiating opioid therapy and (ii) progressing to long-term opioid use, after an osteoarthritis (OA) diagnosis.Methods. Population-based open cohort study using Swedish registers. We followed 48,778 opioid-naïve individuals, aged 35-75, with incident OA between 2008 and 2019 in the Skåne region. The associations of diabetes and hypertension with first opioid dispensation (ATC: N02A) and long-term opioid use (≥90 Defined Daily Doses in one year) were analysed using flexible parametric survival models. Associations were adjusted for sociodemographic characteristics, comorbidities, and prior healthcare use.Results. At OA diagnosis, 26% of individuals had hypertension alone, 3% diabetes alone, and 6% both; 3% developed diabetes during follow-up time, 8% hypertension. Compared to metabolically healthy individuals, the risk of a first opioid dispensation was higher only for those with hypertension alone (RR: 1.16 [95% CI 1.12; 1.20]) and both conditions (RR: 1.15 [1.10; 1.21]). All metabolic conditions were associated with a higher risk of long-term opioid use: diabetes alone (RR: 1.63 [1.21; 2.20]), hypertension alone (RR: 1.32 [1.14; 1.52]), and both (RR: 1.69 [1.42; 2.02]). The instant risk peaked in the first year post-diagnosis, and the cumulative risk was highest in comorbid groups for both outcomes (47.5% and 4.6% with both conditions vs 39.0% and 2.5% with none).Conclusion. After OA diagnosis, hypertension and/or diabetes were associated with an increased risk of initiating opioid therapy and progressing to long-term use. Our findings underscore the need to develop safer OA management strategies for individuals with comorbidities.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.